JPMorgan Chase enters July having given back some of last week's gains, with the stock slipping 2% on the week to $327.33 — a modest retreat that arrives with Q2 results just 13 calendar days away.
The options market has retained its newly relaxed posture even as the stock eased. The put/call ratio closed at 1.07, nearly 1.5 standard deviations below its 20-day mean of 1.26 — close to the year's most bullish options configuration, and a world away from the 52-week high of 1.47 hit on June 15. Previous notes tracked the unwinding of that defensive overhang through June; the current reading confirms it has not reasserted itself despite the price dip. The borrow market reinforces the picture: availability is essentially unlimited — more than 2.6 billion shares remain available to lend — and the cost to borrow has dropped sharply, falling to 0.09% from around 0.38% a week ago. Short interest is barely a rounding error at 1.1% of the free float. Nothing in the lending or options data suggests bears are rebuilding ahead of the print.
The analyst community moved in the same direction. Morgan Stanley's Betsy Graseck raised her price target to $362 on Sunday, maintaining an Equal-Weight rating — a notable lift from $336 that pushes one bellwether's target above the stock's recent range. Truist lifted its target to $344 the day before. The consensus mean now sits at $345, roughly 5% above the current price. Valuations have drifted higher over the past month: the P/E ratio has climbed from roughly 13.4 to 14.5, and price-to-book has expanded by about 0.18 turns to 2.4x. Neither multiple looks stretched for a franchise this size, but both have moved meaningfully. Factor scores give bulls something to work with: the dividend rank scores in the 95th percentile, the EPS 12-month forward growth rank reads 76th percentile, and EPS surprise is at the 72nd percentile — the company has consistently beaten estimates. The bear case, as the Street frames it, centres on credit cost normalization and deposit competition, not on current fundamentals.
Insider selling has been steady but reads as routine. The General Counsel sold just over $1.8 million of stock on June 22, following a cluster of senior executive sales in May — the COO, CFO, Chief Risk Officer, and multiple divisional CEOs all trimmed between May 5 and May 20. None of the trade significance scores exceed 2 out of 10, and the 90-day net share position is actually positive at roughly 344,000 shares when aggregated across all insiders. CEO Jamie Dimon remains the largest individual holder at 6.3 million shares. The selling pattern looks more like scheduled liquidity management than conviction-driven distribution.
JPMorgan's two most recent earnings prints have been muted: the April 14 result delivered a 2.5% one-day decline and was essentially flat five days later; the May 19 print produced a 0.4% gain with a 2% lift over the following week. The stock has not made a dramatic post-earnings move in recent memory, which may partly explain why options traders have stopped paying for downside protection — the PCR's continued deflation into the July 14 event is itself a signal about what the market expects the magnitude of any move to be.
What shifts the setup now is whether Q2 net interest income and credit costs land in line with the revised — and lifted — estimates that drove the May EPS beat. Morgan Stanley's fresh $362 target implies the bar has moved up; the degree of options complacency heading into the print is the data point worth watching as that date approaches.
See the live data behind this article on ORTEX.
Open JPM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
